Danaher Financial Results
Danaher reported third quarter 2026 revenues of $6.6 billion, an 8.5% increase year-over-year, with net earnings rising 34.5% to $1.2 billion. The company raised its full-year 2026 adjusted diluted net earnings per share guidance to a range of $8.57 to $8.62, citing improving trends across end markets.
- Term
- Q3 2026
“We delivered better-than-expected third quarter revenue, earnings and cash flow, and are encouraged by the improving trends we saw across our end markets. The continued acceleration in core revenue growth excluding respiratory revenue, together with DBS-driven execution drove double-digit adjusted EPS growth and underscored our ability to convert improving demand into strong financial performance.”
Julie Sawyer Montgomery, President and Chief Executive Officer
“Looking forward, the opportunity for Danaher is clear: to become the defining leader in Life Sciences and Diagnostics–a company that unambiguously gains share, delivers sustainable profitable growth, and helps our customers improve outcomes for patients around the world.”
Julie Sawyer Montgomery, President and Chief Executive Officer